Title: “New approaches to the crisis in finding therapies for neurodegenerative diseases underlying dementia. (What the ARUK Oxford Drug Discovery Institute can do for you)”
Speaker: Dr John Davies, Chief Scientific Officer of the
Oxford ARUK Drug Discovery Institute
Venue: Rooms B02/B03, SITraN, 385a Glossop Road,
Sheffield S10 2HQ
The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) couples the deep disease knowledge and biology expertise of the academic community with high quality, innovative drug discovery technologies. This initiative is based on juxtaposing high quality drug discovery expertise alongside a deep scientific and academic understanding of patients, disease mechanisms, and model systems. The intent is to translate cutting edge academic science into drug discovery, and to prosecute projects from target to lead status, and beyond.
Housed within The Target Discovery Institute at the University of Oxford, the ODDI is uniting collaborative efforts for target identification with sophisticated target development capabilities. Led by the CSO, Dr John Davis, the ODDI focuses on novel targets in the dementia therapeutic area, bringing together researchers from Biology, Chemistry, Psychiatry, and Neuroscience. The institute is part of a newly formed, world-class, network of three drug discovery institutes, sponsored by Alzheimer’s Research UK.